145 related articles for article (PubMed ID: 38349565)
21. ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.
Miyasaka Y; Nakamura M
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):739-740. PubMed ID: 31538287
[No Abstract] [Full Text] [Related]
22. Adjuvant treatments for resectable pancreatic cancer.
Ueno H; Kosuge T
J Hepatobiliary Pancreat Surg; 2008; 15(5):468-72. PubMed ID: 18836798
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant and neoadjuvant approaches in pancreatic cancer.
Conroy T; Lambert A; Ducreux M
Curr Opin Oncol; 2023 Jul; 35(4):326-333. PubMed ID: 37222189
[TBL] [Abstract][Full Text] [Related]
24. Role of radiation therapy in patients with resectable pancreatic cancer.
Palta M; Willett C; Czito B
Oncology (Williston Park); 2011 Jul; 25(8):715-21, 727. PubMed ID: 21874833
[TBL] [Abstract][Full Text] [Related]
25. ASO Author Reflections: Impact of Neoadjuvant Therapy on Survival After Margin-Positive Resection for Pancreatic Cancer.
Chopra A; Beane JD
Ann Surg Oncol; 2021 Nov; 28(12):7770-7771. PubMed ID: 34028634
[No Abstract] [Full Text] [Related]
26. ASO Author Reflections: Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors-A Single Operation is Feasible in Most Patients.
Gudmundsdottir H; Halfdanarson TR; Cleary SP
Ann Surg Oncol; 2022 Oct; 29(11):6958-6959. PubMed ID: 35780453
[No Abstract] [Full Text] [Related]
27. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J
Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715
[TBL] [Abstract][Full Text] [Related]
28. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer-Standard of Care or Still Worth Debating?
Chawla A; Wang J
Ann Surg Oncol; 2020 Apr; 27(4):1201-1202. PubMed ID: 31848817
[No Abstract] [Full Text] [Related]
29. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?
Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S
Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452
[TBL] [Abstract][Full Text] [Related]
30. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy.
Evans DB; Erickson BA; Ritch P
Ann Surg Oncol; 2010 Nov; 17(11):2803-5. PubMed ID: 20737218
[No Abstract] [Full Text] [Related]
31. ASO Author Reflections: Reducing Subjectivity on Assessment of Pancreatic Cancer Resectability.
Toesca DAS; Chang DT
Ann Surg Oncol; 2023 Jun; 30(6):3489-3490. PubMed ID: 36840863
[No Abstract] [Full Text] [Related]
32. ASO Author Reflections: The Complexity of the Volume-Outcome Relationship in Pancreatic Cancer.
Kemp Bohan PM; Nelson DW
Ann Surg Oncol; 2023 Mar; 30(3):1449-1450. PubMed ID: 36477428
[No Abstract] [Full Text] [Related]
33. ASO Author Reflections: Optimal Technical Management of Pancreatic Transection During Distal Pancreatectomy.
Kondo N; Murakami Y
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):643-644. PubMed ID: 31222682
[No Abstract] [Full Text] [Related]
34. ASO Author Reflections: Minimally Invasive Pancreaticoduodenectomy for Pancreatic Cancer: Are We Maximizing Delivery of Multimodality Therapy?
Dahdaleh F; Naffouje S
Ann Surg Oncol; 2022 Nov; 29(12):7804-7805. PubMed ID: 35963907
[No Abstract] [Full Text] [Related]
35. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
36. ASO Author Reflections: Outcomes Support Aggressive Surgery for Early-Onset Pancreatic Cancer.
Leonhardt CS; Kinny-Köster B; He J; Strobel O
Ann Surg Oncol; 2023 Apr; 30(4):2444-2445. PubMed ID: 36572804
[No Abstract] [Full Text] [Related]
37. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
38. ASO Author Reflections: Postoperative Chemotherapy After Neoadjuvant Therapy and Pancreatectomy for Pancreatic Cancer: Balancing Patient Physiology and Disease Biology.
Kamarajah SK; Dahdaleh F
Ann Surg Oncol; 2021 Oct; 28(11):6803-6804. PubMed ID: 33774772
[No Abstract] [Full Text] [Related]
39. ASO Author Reflections: Lymph Node Metastasis and the Role for Lymphadenectomy During Surgery for Nonfunctional Pancreatic Neuroendocrine Tumors.
Lopez-Aguiar AG; Maithel SK
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):700-701. PubMed ID: 31440924
[No Abstract] [Full Text] [Related]
40. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO).
Brunner TB; Grabenbauer GG; Meyer T; Golcher H; Sauer R; Hohenberger W
BMC Cancer; 2007 Mar; 7():41. PubMed ID: 17338829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
